Dupixent Asthma denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for dupixent asthma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Dupixent for Asthma as Not FDA-Approved — and How to Correct That Denial

A "not FDA-approved" denial for dupilumab (Dupixent) in asthma is most often a coding, documentation, or policy-mapping error. Dupilumab has received FDA approval for use as an add-on maintenance treatment in certain patients with moderate-to-severe asthma. If Aetna issued this denial, the most likely causes are: (1) the diagnosis code on the claim did not align with the FDA-approved indication as written in Aetna's policy; (2) the claim was submitted without documentation establishing the qualifying phenotype; or (3) the plan's system mapped the drug to a different indication that is not FDA-approved.

### Why This Denial Is Appealable

FDA approval is a matter of public record, and an insurer's denial on "not FDA-approved" grounds for an approved use is challengeable under both ERISA §503 and ACA §2719. The FDA-approved prescribing label is your primary exhibit. An external reviewer — who is independent of Aetna — can assess whether Aetna's determination is consistent with the FDA approval and current medical evidence, and external reviewers routinely reverse these denials when the documentation package is complete.

### Your Appeal Timeline

• Internal appeal: File within the deadline on your denial notice (commonly 180 days for ERISA plans). Decisions within 30–60 days; expedited within 72 hours for urgent situations.
• External review: After internal denial, approximately four months to request independent external review. For urgent cases, expedited external review is available with a binding decision within 72 hours.

### Documentation to Gather

1. FDA-approved prescribing information for dupilumab — print the current label from the FDA website and attach it to your appeal. Highlight the asthma indication section. 2. Diagnosis confirmation — pulmonary function tests and specialist notes confirming the diagnosis of moderate-to-severe asthma using the same terminology as the FDA label. 3. Phenotype documentation — laboratory and clinical records establishing the qualifying inflammatory profile described in the FDA-approved indication. 4. Prior controller therapy documentation — records confirming add-on maintenance therapy status as described in the FDA label. 5. Prescriber medical-necessity letter — your physician should quote the FDA-approved indication directly, confirm your diagnosis code maps to it, and explain how your clinical presentation meets the approved use.

### Criteria-Mapping Structure

Obtain Aetna's clinical policy for dupilumab in asthma and compare the stated indication to the FDA label. Address any gap between them:

| Basis for Denial | Your Rebuttal Evidence | |---|---| | Aetna's claim of non-approval | FDA label excerpt confirming asthma indication | | Diagnosis code mismatch (if applicable) | Corrected code with chart documentation | | Missing phenotype documentation | Lab or clinical record establishing qualifying profile |

If the denial was a billing or coding error, a corrected claim (in addition to an appeal) may resolve it faster. Consult your prescriber about whether a corrected submission is appropriate alongside the formal appeal.